These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29411170)

  • 21. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide.
    Watanabe N; Tone Y; Nagata T; Masuda S; Saito T; Motohashi N; Takagaki K; Aoki Y; Takeda S
    Mol Ther Nucleic Acids; 2023 Dec; 34():102034. PubMed ID: 37854955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
    Li D; Mastaglia FL; Fletcher S; Wilton SD
    Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
    Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
    Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
    Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
    Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-targeted splice-correction therapy for neuromuscular disease.
    Wood MJ; Gait MJ; Yin H
    Brain; 2010 Apr; 133(Pt 4):957-72. PubMed ID: 20150322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Making sense of antisense oligonucleotides: A narrative review.
    Goyal N; Narayanaswami P
    Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides.
    Torroba B; Macabuag N; Haisma EM; O'Neill A; Herva ME; Redis RS; Templin MV; Black LE; Fischer DF
    Expert Opin Drug Discov; 2023 Feb; 18(2):181-192. PubMed ID: 36408582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 39. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
    Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.